They reported that among women <37 weeks, an sFlt-1/PlGF ratio ≤ 38 ruled out preeclampsia the following 1 week (NPV 96.2%) and predicted disease over the following 4 weeks (PPV 75%) highlighting its clinical value and the need for adoption in national protocols [92] (Figure 2). This evidence concerns the gene PGF and preeclampsia.